Allogeneic or autologous anti-leukemia CTL directed against minor histocompatibility antigens or the BCR/ABL neoantigen (26–29), have been successfully employed to treat relapsed leukemia in adult patients representing proof of principle for the potential efficacy of this form of T cell therapy. The gene discussed is BCR; the disease is leukemia.